8-K Impact 7/10 M&A

$VTRS · Viatris Inc

November 17, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Viatris filed an 8-K reporting completion of its acquisition of Pacira BioSciences via tender offer and Section 251(h) merger. The offer for $36.50 per share in cash expired Nov 16, 2026, with 32,929,780 shares (66.46%) validly tendered. Pacira is now a wholly owned subsidiary, and its shares will be delisted from Nasdaq.

  • Offer price was $36.50 per share in cash.
  • 32,929,780 shares tendered, representing 66.46% of outstanding shares.
  • Merger completed without Pacira stockholder vote under DGCL Section 251(h).
  • Pacira shares to be delisted from Nasdaq Global Select Market.
  • Viatris expects $90M–$100M revenue contribution for remainder of 2026.
PeriodQ4 2026 (partial)
Guidance rev$90M–$100M for Nov 17–Dec 31, 2026

VTRS traded at $20.64, up 0.61% since filing, a muted reaction consistent with a previously announced deal closing on schedule.

The closing converts a previously announced tender offer into a completed acquisition, adding a non-opioid pain franchise to Viatris's portfolio.

The deal strengthens Viatris's U.S. innovative medicines business and establishes a non-opioid pain management position.

Viatris may not realize anticipated benefits, synergies, or operating efficiencies from the Pacira acquisition.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →